Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were treated with trastuzumab plus docetaxel. Pathological complete and partial responses were documented for nine (39%) and 14 (61%) patients, respectively. Case-matched controls comprised patients treated with docetaxel-based PST without trastuzumab (D; n=23) or PST without docetaxel or trastuzumab (non-taxane, non-trastuzumab, NT-NT; n=23). All surgical specimens were blind-analysed by two independent pathologists, with immunohistochemical evaluation of B and T lymphocytes, macrophages, dendritic cells and natural killer (NK) cells. Potential cytolytic cells were stained for Granzyme B and TiA1. HER2 expression was also evaluated in residual tumour cells. Trastuzumab treatment was associated with significantly increased numbers of tumour-associated NK cells and increased lymphocyte expression of Granzyme B and TiA1 compared with controls. This study supports an in vivo role for immune (particularly NK cell) responses in the mechanism of trastuzumab action in breast cancer. These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 3×
“Approximately 20–30% of all breast cancers overexpress HER2 (Slamon et al, 1987; van de Vijver et al, 1988; Ross et al, 2003; Owens et al, 2004).”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 3×
“I 1 3 1 II 9 9 8 III 13 11 14”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“…is a monoclonal antibody that binds to the surfaces of HER2-overexpressing cancer cells, it has been postulated that ADCC may play an important role in the mechanism of action of this drug (Cooley et al, 1999; Clynes et al, 2000; Carson et al, 2001; Repka et al, 2003; Gennari et al, 2004).”
BackgroundCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
Singletary, S. E., Allred, C., Ashley, P., Bassett, L. W., Berry, D., Bland, K. I., Borgen, P. I., Clark, G., Edge, S. B., Hayes, D. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.026 · Cited by 1,173
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Cited by
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 863
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 828
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Activation, coactivation, and costimulation of resting human natural killer cells
Bryceson, Y. T., March, M. E., Ljunggren, H., & Long, E. O. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00457.x · Cited by 650
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 606
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
“Consistently, an increase of tumor-infiltrating leukocytes, especially FcR+ cells such as NK cells, has been observed in tumor tissue after antibody treatment (Arnould et al., 2006; Varchetta et al., 2007).”
BackgroundBibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Self-citationStagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Spector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494
Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 415
Fehrenbacher, L., Cecchini, R. S., Geyer Jr, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J.-F., Provencher, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01455 · Cited by 404
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Pierpont, T. M., Limper, C. B., & Richards, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00163 · Cited by 374
West, N. R., Milne, K., Truong, P. T., Macpherson, N., Nelson, B. H., & Watson, P. H. (2011) · Breast Cancer Research · doi:10.1186/bcr3072 · Cited by 356
Rugo, H. S., Im, S.-A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7932 · Cited by 343
Trastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
Ladoire, S., Arnould, L., Apetoh, L., Coudert, B., Martin, F., Chauffert, B., Fumoleau, P., & Ghiringhelli, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4491 · Cited by 310
Self-citationThe immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 286
How to select IgG subclasses in developing anti-tumor therapeutic antibodies
Yu, J., Song, Y., & Tian, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00876-4 · Cited by 269
Shi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402891 · Cited by 195
“Studies have shown that higher affinity interactions between Ab and FcgRs promote more robust ADCC and ADCP activities and are associated with better therapeutic efficacy of the anti-CD20 Ab rituximab (24, 25).”
BackgroundInfluentialTargeting the function of the HER2 oncogene in human cancer therapeutics
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210478 · Cited by 190
“Consistent with this, three clinical studies show no reduction in tumor HER2 expression in patients undergoing treatment with trastuzumab (Gennari et al., 2004; Mohsin et al., 2005; Arnould et al., 2006).”
BackgroundNguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S. S., Cossutta, M., Khira, Y., Han, W., Sirven, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.015 · Cited by 184
“dent cell-mediated cytotoxicity [ADCC]) (Arnould et al., 2006; Clynes et al., 2000; Kute et al., 2012; Varchetta et al., 2007).”
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Triulzi, T., Regondi, V., De Cecco, L., Cappelletti, M. R., Di Modica, M., Paolini, B., Lollini, P. L., Di Cosimo, S., Sfondrini, L., Generali, D., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0318-0 · Cited by 94
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Mo, C., Sterpi, M., Jeon, H., & Bteich, F. (2024) · Cancers · doi:10.3390/cancers16162854 · Cited by 8
“While the extracellular mechanisms of action of trastuzumab are well understood, including its immune effector functions such as CDC and CDCC, its intracellular actions are still being investigated [24–26].”
Background
Metadata
- Authors
- Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., Jeannin, J.-F., & Coudert, B.
- Venue
- British Journal of Cancer
- Published
- 2006-01
- Volume
- 94
- Issue
- 2
- Pages
- 259-267
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2027542837
- Cited by
- 545
- References
- 32
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.